Latest news with #CGRP
Yahoo
08-07-2025
- Business
- Yahoo
Teva's Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial
Teva Pharmaceutical (NYSE:TEVA) is one of the most undervalued large cap stocks to buy according to analysts. On June 24, Teva Pharmaceutical announced the final analysis results from its PEARL Phase IV migraine prevention trial for Ajovy (fremanezumab), which is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody. The study included individuals with both chronic and episodic migraine and confirmed the achievement of its primary and secondary endpoints. The final data demonstrated that over 66% of EM patients and 51.6% of CM patients who met the primary goal within the initial 6 months continued to experience significant benefits in migraine prevention for more than 24 months. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Furthermore, the trial observed high injection adherence rates, nearing 90%, throughout the study duration, with over 75% of subjects completing the full 24-month study. The long-term tolerability and safety profile of fremanezumab remained consistent with previous interim analyses and randomized controlled studies. Teva Pharmaceutical (NYSE:TEVA) develops, manufactures, markets, and distributes generic and other medicines and biopharmaceutical products in the US, Europe, Israel, and internationally. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Health Line
06-07-2025
- Health
- Health Line
Medication for Migraine Headaches
Key Takeaways Medications for migraine either prevent episodes or relieve symptoms, with options like pills, injections, and nasal sprays available. Acute medications provide relief during a migraine, while preventive medications reduce the frequency and severity of episodes. Some people may need both. Various acute and preventive medications exist, including pain relievers, ergotamines, triptans, CGRP antagonists, anti-nausea drugs, and others like beta-blockers and antidepressants. Migraine is a condition in which you experience severe, debilitating headaches, involving intense throbbing or pulsing in one area of your head. The headaches are often accompanied by nausea, vomiting, and sensitivity to light and sound. There's no cure for migraine, but some medications can provide pain relief and improve your quality of life. There are two categories of medications used to help treat migraine: Acute medications: These help provide relief from pain and other symptoms during a migraine attack. Preventive medications: These aim to reduce the frequency and severity of chronic migraine attacks. Some people may need medications for acute treatment only, while others may need a combination of the two types of medication. The best treatment plan will depend on the type, severity, and frequency of your migraine attacks. Keep reading to learn more about the different types of medications to help treat migraine. Drugs for acute treatment These medications should be taken at the onset of migraine symptoms to relieve a headache, reduce its severity, or prevent it from progressing. Taking any of these drugs too often may lead to a medication overuse (rebound) headache. This type of headache may arise from overusing medication and adapting to its effects. If you need to use acute migraine drugs more than 10 days per month, speak with a healthcare professional. They may suggest other treatments, such as preventive medications. Here are the different types of acute medications for migraine: Pain relievers Some over-the-counter (OTC) pain relievers may help treat migraine. These include: Some OTC drugs marketed specifically for migraine combine one or more of the drugs above with a small amount of caffeine. This can make them work more quickly and effectively, especially for mild migraine. If OTC pain relievers don't help treat migraine symptoms, a doctor may prescribe stronger doses. But it's important to be aware of the possible side effects of long-term NSAID use. These include: Learn more about OTC medications for migraine. Ergotamines Ergotamines were the first class of drugs used specifically for migraine. They help treat vascular headaches by targeting 5HT-1B and 5HT-1D receptors, which contract the blood vessels around your brain. They're not commonly prescribed anymore since more effective medications are now available. They also have potentially dangerous side effects that could affect your brain, heart, and cardiovascular system. But if your migraine attacks are frequent or last longer than 48 hours, a doctor may still recommend some ergotamines, such as: dihydroergotamine (DHE-45, Migranal) ergotamine (Ergomar) ergotamine and caffeine (Cafatine, Cafergot, Cafetrate, Ercaf, Migergot, Wigraine) Talk with a healthcare professional before taking ergotamines, especially if you: are pregnant have heart disease are taking other medications, such as antifungals or antibiotics Triptans Triptans increase serotonin levels in your brain, reducing inflammation and constricting blood vessels to effectively end a migraine attack. Triptans are available in the form of pills, nasal sprays, injections, and tablets that dissolve under your tongue, and they work quickly to stop a migraine attack. Triptans available to help treat migraine include: almotriptan (Axert) eletriptan (Relpax) frovatriptan (Frova) naratriptan (Amerge) rizatriptan (Maxalt, Maxalt-MLT) sumatriptan (Imitrex) zolmitriptan (Zomig) You should not take triptans more than 10 times per month. Additionally, you should not take triptans if you: have had a stroke have heart disease have hypertension (high blood pressure) have angina are pregnant have hemiplegia have basilar migraine Possible side effects of triptans include: drowsiness hot or cold flashes dizziness nausea tingling or numbness in your toes tightness or discomfort in your chest or throat Triptans may also cause serotonin syndrome if taken with other drugs that increase serotonin, such as antidepressants. This may be life threatening. Learn more about triptans for migraine. Calcitonin gene-related peptide (CGRP) antagonists CGRP antagonists, also known as gepants, are the newest group of medications approved for treating and preventing migraine. They work on calcitonin gene-related peptide (CGRP), a protein found around your brain that is involved in the pain associated with migraine. Current CGRP antagonists approved to treat acute migraine include: rimegepant (Nurtec) ubrogepant (Ubrelvy) zavegepant (Zavzpret) Learn more about CGRP antagonists for migraine. Anti-nausea drugs These drugs may help reduce nausea and vomiting that can occur during a severe migraine episode. They're usually taken along with a pain reliever since they don't reduce pain. Anti-nausea medications include: dimenhydrinate (Gravol) metoclopramide (Reglan) prochlorperazine (Compazine) promethazine (Phenergan) trimethobenzamide (Tigan) These drugs may make you drowsy, less alert, or dizzy, and they have other possible side effects. Learn more about anti-nausea medications. Opioids If migraine pain doesn't respond to other pain relievers and you can't take ergotamines or triptans, you may receive opioids during hospitalization for migraine. However, some research suggests that opioid use may increase the risk of effects such as: worse headaches opioid dependence reduced quality of life For this reason, it's important to discuss other treatment options with a healthcare professional. Drugs for preventive treatment If you're living with chronic migraine, a healthcare professional may prescribe a medication to help: prevent migraine episodes reduce symptom intensity, duration, and severity improve your quality of life Possible preventive medications for migraine include: CGRP monoclonal antibodies, such as erenumab (Aimovig), fremanezumab (Ajovy), eptinezumab (Vyepti), and galcanezumab (Emgality) CGRP receptor antagonists, such as atogepant (Qulipta) and rimegepant (Nurtec) beta-blockers, such as metoprolol (Toprol XL) and propranolol (Inderal) calcium channel blockers, such as diltiazem (Cardizem, Cartia XT, Dilacor, Tiazac) and verapamil (Calan, Covera, Isoptin, Verelan) antidepressants, such as amitriptyline (Elavil, Endep) and fluoxetine (Prozac, Sarafem) anticonvulsants, such as topiramate (Topamax) and valproate (Depakene) These drugs are taken on a regular basis, usually daily, and may be prescribed alone or in combination with other drugs. It may take several weeks or months for them to become effective. The Food and Drug Administration (FDA) has also approved Botox (Botulinum toxin type A) injections for the treatment of chronic migraine. Generally, injections are repeated every 3 months and can be costly. Speak with a healthcare professional about the potential side effects of each medication. Frequently asked questions What is the best medication for migraine? The best medication will depend on the frequency, severity, and intensity of your migraine. If you sometimes experience migraine, then OTC or prescription pain relievers may be enough. However, if you experience migraine attacks more than 10 days per month, you may need preventive medications. What is the drug of choice for migraine attacks? Many drugs are effective and recommended for migraine treatment. The best medication will depend on several factors, such as the type and severity of your migraine attacks and any underlying health conditions you have. What is the first-line choice for migraine prevention? First-line medications for migraine episode prevention include divalproex, timolol, frovatriptan, metoprolol, topiramate, and propranolol.
Medscape
02-07-2025
- Health
- Medscape
Erenumab Not Effective for Chronic Cluster Headache
TOPLINE: Preventive treatment with the calcitonin gene-related peptide (CGRP) receptor monoclonal antibody erenumab for 6 weeks was not associated with significant reductions in weekly headache attacks, pain severity, or attack duration in adults with chronic cluster headache (CCH), a new phase 2 placebo-controlled trial showed. METHODOLOGY: The CHERUB01 phase 2 12-week, double-blind, placebo-controlled randomized clinical trial was conducted at 11 sites in Germany between 2021 and 2023. About 81 adults with CCH (mean age, 49 years; 74% men) who failed to respond to standard prophylactic therapies were randomly assigned to receive either subcutaneous erenumab (280 mg at baseline, followed by 140 mg at week 4) or a matching placebo. The primary endpoint was change in the mean number of weekly CH attacks from baseline to weeks 5 and 6. Secondary endpoints included the proportion of patients achieving a ≥ 50% reduction in attacks and the number of participants with Patient Global Impression of Improvement (PGI-I) scores of 1 or 2 at week 6. Exploratory endpoints included reduction in CH attack duration and change in mean pain severity on the numeric pain rating scale. TAKEAWAY: The primary endpoint was not met. Although there was a greater reduction in the mean number of weekly attacks for the erenumab group compared to the placebo group, the difference was not statistically significant (-7.3 vs -5.9 attacks per week; 95% credible interval, -5.7 to 2.8). There was no significant difference between groups in the proportion of participants achieving a ≥ 50% reduction in weekly attacks, the number of patients with improved PGI-I scores, changes in attack duration, or change in pain severity. Adverse events were more common in the erenumab group compared to the placebo group (66% vs 43%), with most considered to be mild or moderate. IN PRACTICE: 'Erenumab failed to show a benefit over placebo in patients with CCH, indicating that blockade of peripheral CGRP receptors has no beneficial role in the prophylaxis of CCH,' the investigators wrote. 'To date, all double-blind controlled trials in CCH using an mAb affecting the CGRP pathway were negative, leading to the conclusion that future research should revisit the role of CGRP in CCH,' they added. SOURCE: This study was led by Jasper Mecklenburg, MD, Charité – UniversitätsmedizinBerlin, Berlin, Germany. It was published online on June 17 in JAMA Network Open. LIMITATIONS: Data on patients who progressed from episodic headache to CCH were missing. Additionally, the onset timing of current CCH episodes was unclear, with no detailed records of past steroid responses or reasons for prior treatment failures with verapamil or lithium, which relied on patient recall. DISCLOSURES: This trial was funded by a grant from Novartis Pharma GmbH to Charité – UniversitätsmedizininBerlin. Several investigators reported having financial ties with various sources including the funding company. Full details are listed in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
26-06-2025
- Health
- Yahoo
Teva reports final analysis of migraine prevention trial of Ajovy
Teva Pharmaceutical has reported the final analysis of the PEARL Phase IV migraine prevention trial of the anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, Ajovy (fremanezumab), in individuals with chronic and episodic migraine (EM). The pan-European study's data confirmed that the primary and secondary endpoints were achieved. The primary goal was the proportion of subjects experiencing at least a 50% decrease in the number of monthly migraine days (MMD) in the six months after starting fremanezumab treatment. Secondary goals included the mean change from baseline in MMD and treatment adherence and persistence rates over 24 months. The trial involved 1,140 subjects, 33.1% with EM and 66.9% with chronic migraine (CM). The final data indicated that over 66% of EM patients and 51.6% of CM patients who met the primary goal during the first six months continued to see a significant benefit in migraine prevention for more than 24 months. High injection adherence rates of nearly 90% were observed throughout the trial, with more than 75% of subjects completing the full study duration. According to the investigators, the long-term tolerability and safety profile of the treatment was also consistent with prior interim analyses and randomised controlled studies. This supports the continued clinical use of Ajovy for migraine prevention. Teva Pharmaceutical Medical Affairs Europe head and vice-president Pinar Kokturk said: 'The final analysis of the PEARL real-world study reaffirms the long-term effectiveness and safety profile of fremanezumab in the preventive treatment of chronic and episodic migraine. 'These data provide valuable real-world evidence supporting fremanezumab's sustained clinical benefit, particularly in a population burdened by high disease impact and a need for preventive therapy.' Last year, Teva reported positive outcomes from the Phase III SPACE trial of Ajovy as a preventive treatment for EM in young patients aged six to 17 years old. "Teva reports final analysis of migraine prevention trial of Ajovy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial
AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive. The study evaluated the tolerability, safety, and efficacy of atogepant (marketed as QULIPTA or AQUIPTA) compared to topiramate for the preventive treatment of migraine in adults. A clinical researcher in a lab examining a new biopharmaceutical product. Atogepant is an oral medication taken once daily to prevent migraines. It works by specifically blocking the activity of a natural messenger molecule in the patient's body called Calcitonin Gene-Related Peptide (CGRP). When CGRP is highly active, it can trigger migraine attacks. Atogepant essentially acts like a 'bouncer,' occupying the 'receptors' or 'docking stations' where CGRP would normally attach. As a result, it prevents CGRP from sending pain signals and significantly reduces how often migraines occur. According to the published results, atogepant successfully met its primary endpoint. The medication demonstrated fewer treatment discontinuations attributed to adverse events (AEs) than topiramate. AbbVie Inc. (NYSE:ABBV) is an American biopharmaceutical company with global operations. It discovers, develops, and markets medicines across several therapeutic areas, including immunology, oncology, neuroscience, eye care, and virology. Its major products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox, and Vraylar. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Biotech Stocks Screaming a Buy and 13 Best Software Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
